Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Open-label, Uncontrolled, Dose-escalation Study of ONO-7475 Given as Monotherapy and Combinations With ONO-4538 in Patients With Advanced or Metastatic Solid Tumors

To evaluate the tolerability and safety of ONO-7475 monotherapy and combinations with ONO-4538 in patients with advanced or metastatic solid tumors

Inclusion Criteria:

• Patients with histologically or cytologically confirmed advanced or metastatic solid tumors
• ECOG Performance Status 0～1
• Patients with life expectancy of at least 3 months

Exclusion Criteria:

• Patients with history of severe allergy
• Patients with multiple cancers